CN101619361A - Hgfr的高亲和力结合位点和鉴定其拮抗剂的方法 - Google Patents
Hgfr的高亲和力结合位点和鉴定其拮抗剂的方法 Download PDFInfo
- Publication number
- CN101619361A CN101619361A CN 200910136732 CN200910136732A CN101619361A CN 101619361 A CN101619361 A CN 101619361A CN 200910136732 CN200910136732 CN 200910136732 CN 200910136732 A CN200910136732 A CN 200910136732A CN 101619361 A CN101619361 A CN 101619361A
- Authority
- CN
- China
- Prior art keywords
- ipt
- hgf
- met
- growth factor
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims description 36
- 239000005557 antagonist Substances 0.000 title claims description 18
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 claims abstract description 76
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 66
- 239000003814 drug Substances 0.000 claims abstract description 27
- 201000011510 cancer Diseases 0.000 claims abstract description 24
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 11
- 238000012216 screening Methods 0.000 claims abstract description 11
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 8
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 8
- 239000002157 polynucleotide Substances 0.000 claims abstract description 8
- 229920001184 polypeptide Polymers 0.000 claims abstract description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 4
- 102000008022 Proto-Oncogene Proteins c-met Human genes 0.000 claims abstract 16
- 210000004027 cell Anatomy 0.000 claims description 99
- 239000003112 inhibitor Substances 0.000 claims description 21
- 230000000694 effects Effects 0.000 claims description 20
- 238000001514 detection method Methods 0.000 claims description 19
- 238000011282 treatment Methods 0.000 claims description 9
- 239000002773 nucleotide Substances 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 claims description 7
- 238000011275 oncology therapy Methods 0.000 claims description 5
- 230000004083 survival effect Effects 0.000 claims description 5
- 230000003197 catalytic effect Effects 0.000 claims description 4
- 108020004459 Small interfering RNA Proteins 0.000 claims description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 2
- 230000000692 anti-sense effect Effects 0.000 claims description 2
- 230000004663 cell proliferation Effects 0.000 claims description 2
- 230000005754 cellular signaling Effects 0.000 claims 1
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 abstract 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 abstract 1
- 210000003370 receptor cell Anatomy 0.000 abstract 1
- 102100022623 Hepatocyte growth factor receptor Human genes 0.000 description 60
- 108090000623 proteins and genes Proteins 0.000 description 43
- 235000018102 proteins Nutrition 0.000 description 32
- 102000004169 proteins and genes Human genes 0.000 description 32
- 108020004414 DNA Proteins 0.000 description 25
- 238000004458 analytical method Methods 0.000 description 24
- 241000699666 Mus <mouse, genus> Species 0.000 description 22
- 101100042271 Mus musculus Sema3b gene Proteins 0.000 description 22
- 230000027455 binding Effects 0.000 description 20
- 239000013598 vector Substances 0.000 description 19
- 238000010361 transduction Methods 0.000 description 18
- 230000026683 transduction Effects 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 17
- 150000001875 compounds Chemical class 0.000 description 16
- 102100024263 CD160 antigen Human genes 0.000 description 14
- 210000004899 c-terminal region Anatomy 0.000 description 14
- 230000008034 disappearance Effects 0.000 description 14
- 238000003119 immunoblot Methods 0.000 description 14
- 230000001939 inductive effect Effects 0.000 description 14
- 102000005962 receptors Human genes 0.000 description 13
- 108020003175 receptors Proteins 0.000 description 13
- 230000008521 reorganization Effects 0.000 description 12
- 239000007790 solid phase Substances 0.000 description 12
- 238000012546 transfer Methods 0.000 description 12
- 210000005239 tubule Anatomy 0.000 description 12
- 238000001114 immunoprecipitation Methods 0.000 description 11
- 108010035532 Collagen Proteins 0.000 description 9
- 102000008186 Collagen Human genes 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 9
- 102000027430 HGF receptors Human genes 0.000 description 9
- 108091008603 HGF receptors Proteins 0.000 description 9
- 230000004913 activation Effects 0.000 description 9
- 239000007791 liquid phase Substances 0.000 description 9
- 230000026731 phosphorylation Effects 0.000 description 9
- 238000006366 phosphorylation reaction Methods 0.000 description 9
- 102000016844 Immunoglobulin-like domains Human genes 0.000 description 8
- 108050006430 Immunoglobulin-like domains Proteins 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000002623 insulin potentiation therapy Methods 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 108091000080 Phosphotransferase Proteins 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 238000001574 biopsy Methods 0.000 description 6
- 201000001441 melanoma Diseases 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 102000020233 phosphotransferase Human genes 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 108010079709 Angiostatins Proteins 0.000 description 5
- 108010076504 Protein Sorting Signals Proteins 0.000 description 5
- 150000001413 amino acids Chemical group 0.000 description 5
- 230000029578 entry into host Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000009545 invasion Effects 0.000 description 5
- 238000000386 microscopy Methods 0.000 description 5
- 238000013508 migration Methods 0.000 description 5
- 230000009871 nonspecific binding Effects 0.000 description 5
- 229920002704 polyhistidine Polymers 0.000 description 5
- 230000017854 proteolysis Effects 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 102400000068 Angiostatin Human genes 0.000 description 4
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 108010022999 Serine Proteases Proteins 0.000 description 4
- 102000012479 Serine Proteases Human genes 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000034303 cell budding Effects 0.000 description 4
- 239000013592 cell lysate Substances 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- 238000006471 dimerization reaction Methods 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 238000001415 gene therapy Methods 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 238000002991 immunohistochemical analysis Methods 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000000452 restraining effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 101100179915 Arabidopsis thaliana IPT3 gene Proteins 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 3
- 102000014105 Semaphorin Human genes 0.000 description 3
- 108050003978 Semaphorin Proteins 0.000 description 3
- 102100022346 Serine/threonine-protein phosphatase 5 Human genes 0.000 description 3
- 102000013275 Somatomedins Human genes 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 108091093126 WHP Posttrascriptional Response Element Proteins 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 229960001134 von willebrand factor Drugs 0.000 description 3
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102100031277 Calcineurin B homologous protein 1 Human genes 0.000 description 2
- 101710205625 Capsid protein p24 Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 206010015548 Euthanasia Diseases 0.000 description 2
- 102000009331 Homeodomain Proteins Human genes 0.000 description 2
- 108010048671 Homeodomain Proteins Proteins 0.000 description 2
- 101000654674 Homo sapiens Semaphorin-6A Proteins 0.000 description 2
- 101000624356 Homo sapiens tRNA dimethylallyltransferase Proteins 0.000 description 2
- 101150085452 IPT1 gene Proteins 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 101710177166 Phosphoprotein Proteins 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 102100032795 Semaphorin-6A Human genes 0.000 description 2
- 101710129069 Serine/threonine-protein phosphatase 5 Proteins 0.000 description 2
- 101710149279 Small delta antigen Proteins 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 230000002001 anti-metastasis Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000011888 autopsy Methods 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 201000005296 lung carcinoma Diseases 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000001806 memory b lymphocyte Anatomy 0.000 description 2
- 238000011235 metanalysis Methods 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 230000007026 protein scission Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000000235 small-angle X-ray scattering Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- FPYJSJDOHRDAMT-KQWNVCNZSA-N 1h-indole-5-sulfonamide, n-(3-chlorophenyl)-3-[[3,5-dimethyl-4-[(4-methyl-1-piperazinyl)carbonyl]-1h-pyrrol-2-yl]methylene]-2,3-dihydro-n-methyl-2-oxo-, (3z)- Chemical compound C=1C=C2NC(=O)\C(=C/C3=C(C(C(=O)N4CCN(C)CC4)=C(C)N3)C)C2=CC=1S(=O)(=O)N(C)C1=CC=CC(Cl)=C1 FPYJSJDOHRDAMT-KQWNVCNZSA-N 0.000 description 1
- BMUDPLZKKRQECS-UHFFFAOYSA-K 3-[18-(2-carboxyethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethylporphyrin-21,24-diid-2-yl]propanoic acid iron(3+) hydroxide Chemical compound [OH-].[Fe+3].[N-]1C2=C(C)C(CCC(O)=O)=C1C=C([N-]1)C(CCC(O)=O)=C(C)C1=CC(C(C)=C1C=C)=NC1=CC(C(C)=C1C=C)=NC1=C2 BMUDPLZKKRQECS-UHFFFAOYSA-K 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 101100179914 Arabidopsis thaliana IPT2 gene Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 101000925662 Enterobacteria phage PRD1 Endolysin Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 101500025915 Homo sapiens Angiostatin Proteins 0.000 description 1
- 101000672307 Homo sapiens Protein unc-50 homolog Proteins 0.000 description 1
- 101000620653 Homo sapiens Serine/threonine-protein phosphatase 5 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 101150008942 J gene Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 241001417092 Macrouridae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 108010047956 Nucleosomes Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102100040294 Protein unc-50 homolog Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- 235000009233 Stachytarpheta cayennensis Nutrition 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000000516 activation analysis Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 101150036080 at gene Proteins 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 238000011953 bioanalysis Methods 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 238000010231 histologic analysis Methods 0.000 description 1
- 208000018875 hypoxemia Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000001597 immobilized metal affinity chromatography Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005567 liquid scintillation counting Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000001002 morphogenetic effect Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 210000001623 nucleosome Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000002384 proinvasive effect Effects 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003939 radioactivation analysis Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229940048102 triphosphoric acid Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- -1 urea glycosides Chemical class 0.000 description 1
- 230000004862 vasculogenesis Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 108010047303 von Willebrand Factor Proteins 0.000 description 1
- 102100036537 von Willebrand factor Human genes 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B60—VEHICLES IN GENERAL
- B60R—VEHICLES, VEHICLE FITTINGS, OR VEHICLE PARTS, NOT OTHERWISE PROVIDED FOR
- B60R21/00—Arrangements or fittings on vehicles for protecting or preventing injuries to occupants or pedestrians in case of accidents or other traffic risks
- B60R21/01—Electrical circuits for triggering passive safety arrangements, e.g. airbags, safety belt tighteners, in case of vehicle accidents or impending vehicle accidents
- B60R21/015—Electrical circuits for triggering passive safety arrangements, e.g. airbags, safety belt tighteners, in case of vehicle accidents or impending vehicle accidents including means for detecting the presence or position of passengers, passenger seats or child seats, and the related safety parameters therefor, e.g. speed or timing of airbag inflation in relation to occupant position or seat belt use
- B60R21/01512—Passenger detection systems
- B60R21/01544—Passenger detection systems detecting seat belt parameters, e.g. length, tension or height-adjustment
- B60R21/01546—Passenger detection systems detecting seat belt parameters, e.g. length, tension or height-adjustment using belt buckle sensors
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B60—VEHICLES IN GENERAL
- B60R—VEHICLES, VEHICLE FITTINGS, OR VEHICLE PARTS, NOT OTHERWISE PROVIDED FOR
- B60R21/00—Arrangements or fittings on vehicles for protecting or preventing injuries to occupants or pedestrians in case of accidents or other traffic risks
- B60R21/02—Occupant safety arrangements or fittings, e.g. crash pads
- B60R21/16—Inflatable occupant restraints or confinements designed to inflate upon impact or impending impact, e.g. air bags
- B60R21/23—Inflatable members
- B60R21/231—Inflatable members characterised by their shape, construction or spatial configuration
- B60R21/2334—Expansion control features
- B60R21/2342—Tear seams
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B60—VEHICLES IN GENERAL
- B60R—VEHICLES, VEHICLE FITTINGS, OR VEHICLE PARTS, NOT OTHERWISE PROVIDED FOR
- B60R21/00—Arrangements or fittings on vehicles for protecting or preventing injuries to occupants or pedestrians in case of accidents or other traffic risks
- B60R21/01—Electrical circuits for triggering passive safety arrangements, e.g. airbags, safety belt tighteners, in case of vehicle accidents or impending vehicle accidents
- B60R2021/01204—Actuation parameters of safety arrangents
- B60R2021/01211—Expansion of air bags
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B60—VEHICLES IN GENERAL
- B60R—VEHICLES, VEHICLE FITTINGS, OR VEHICLE PARTS, NOT OTHERWISE PROVIDED FOR
- B60R21/00—Arrangements or fittings on vehicles for protecting or preventing injuries to occupants or pedestrians in case of accidents or other traffic risks
- B60R21/02—Occupant safety arrangements or fittings, e.g. crash pads
- B60R21/16—Inflatable occupant restraints or confinements designed to inflate upon impact or impending impact, e.g. air bags
- B60R21/23—Inflatable members
- B60R21/231—Inflatable members characterised by their shape, construction or spatial configuration
- B60R21/2334—Expansion control features
- B60R21/2338—Tethers
- B60R2021/23382—Internal tether means
- B60R2021/23384—Internal tether means having ends which are movable or detachable during deployment
Landscapes
- Engineering & Computer Science (AREA)
- Mechanical Engineering (AREA)
- Air Bags (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (11)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08159754.4 | 2008-07-04 | ||
EP20080159754 EP2141051B1 (en) | 2008-07-04 | 2008-07-04 | Air bag arrangement |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101619361A true CN101619361A (zh) | 2010-01-06 |
Family
ID=40043082
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200910136732 Pending CN101619361A (zh) | 2008-07-04 | 2009-05-13 | Hgfr的高亲和力结合位点和鉴定其拮抗剂的方法 |
CN 200910150215 Active CN101618706B (zh) | 2008-07-04 | 2009-06-19 | 一种气囊装置 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200910150215 Active CN101618706B (zh) | 2008-07-04 | 2009-06-19 | 一种气囊装置 |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP2141051B1 (zh) |
CN (2) | CN101619361A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104628867A (zh) * | 2015-01-23 | 2015-05-20 | 同济大学苏州研究院 | 一种肝细胞生长因子受体关键结构域融合蛋白及其应用 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105480183B (zh) * | 2014-10-06 | 2019-04-19 | 福特全球技术公司 | 具有可重构的内部的车辆中的多级安全气囊 |
CN111016840B (zh) * | 2019-12-05 | 2021-10-15 | 宁波吉利汽车研究开发有限公司 | 座椅气囊控制系统、控制方法及汽车 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5762367A (en) * | 1997-04-10 | 1998-06-09 | General Motors Corporation | Air bag module with inflation control device |
DE19816080B4 (de) * | 1998-04-09 | 2006-03-02 | Volkswagen Ag | Sicherheitsvorrichtung für ein Kraftfahrzeug mit einem Airbag, insbesondere einem Beifahrerairbag |
US6454300B1 (en) | 2001-02-27 | 2002-09-24 | Delphi Technologies, Inc. | Air bag tether release assembly |
US6986529B2 (en) * | 2002-04-23 | 2006-01-17 | Trw Vehicle Safety Systems Inc. | Air bag module with vent |
GB2410593A (en) | 2004-02-02 | 2005-08-03 | Autoliv Dev | Safety arrangement for motor vehicles |
US7552942B2 (en) * | 2005-06-23 | 2009-06-30 | Trw Vehicle Safety Systems Inc. | Vehicle occupant protection apparatus having vent member that is controlled by a releasable tether |
US7618061B2 (en) | 2006-04-25 | 2009-11-17 | Trw Vehicle Safety Systems Inc. | Air bag module with releasable tether |
-
2008
- 2008-07-04 EP EP20080159754 patent/EP2141051B1/en active Active
-
2009
- 2009-05-13 CN CN 200910136732 patent/CN101619361A/zh active Pending
- 2009-06-19 CN CN 200910150215 patent/CN101618706B/zh active Active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104628867A (zh) * | 2015-01-23 | 2015-05-20 | 同济大学苏州研究院 | 一种肝细胞生长因子受体关键结构域融合蛋白及其应用 |
Also Published As
Publication number | Publication date |
---|---|
EP2141051A1 (en) | 2010-01-06 |
CN101618706A (zh) | 2010-01-06 |
EP2141051B1 (en) | 2012-08-29 |
CN101618706B (zh) | 2013-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101509263B1 (ko) | Hgfr의 고친화성 결합부위 및 이의 길항물질 동정 방법 | |
US20040038394A1 (en) | Expression vector using for animal cell | |
Young et al. | Isolation and characterization of a new cellular oncogene encoding a protein with multiple potential transmembrane domains | |
US6331302B1 (en) | Protein tyrosine kinase agonist antibodies | |
Barbas et al. | Differential splicing and alternative polyadenylation generates distinct NCAM transcripts and proteins in the mouse. | |
CN101619361A (zh) | Hgfr的高亲和力结合位点和鉴定其拮抗剂的方法 | |
Rupp et al. | Chicken NFI/TGGCA proteins are encoded by at least three independent genes: NFI-A, NFI-B and NFI-C with homologues in mammalian genomes | |
Yao et al. | Neural specificity of elav expression: defining a Drosophila promoter for directing expression to the nervous system | |
Wozniak et al. | POM152 is an integral protein of the pore membrane domain of the yeast nuclear envelope. | |
Howard et al. | Region-specific alleles of the Drosophila segmentation gene hairy. | |
Mahoney et al. | The fat tumor suppressor gene in Drosophila encodes a novel member of the cadherin gene superfamily | |
Brown et al. | The mouse dystonia musculorum gene is a neural isoform of bullous pemphigoid antigen 1 | |
Kutish et al. | Characterization of the latency-related transcriptionally active region of the bovine herpesvirus 1 genome | |
EP0804572A1 (en) | Protein tyrosine kinase agonist antibodies | |
US5585476A (en) | Molecular cloning and expression of G-protein coupled receptors | |
Valinsky et al. | Restriction fragment length polymorphism in sheep at the growth hormone locus is the result of variation in gene number | |
Dixon et al. | Detection and characterization of the fibroblast growth factor-related oncoprotein INT-2 | |
Santoni et al. | Analysis of cDNA clones that code for the transmembrane forms of the mouse neural cell adhesion molecule (NCAM) and are generated by alternative RNA splicing | |
CN108607103B (zh) | Foxd1在制备治疗和/或预防动物骨关节炎产品中的应用 | |
KR20170138539A (ko) | 표피 성장 인자 수용체(egfr)의 세포외 도메인 내에 돌연변이를 갖는 환자를 3종의 완전 인간 단클론성 항-egfr 항체의 조합물로 치료하는 방법 | |
CN114478726B (zh) | 链霉亲和素第27位丝氨酸突变的突变蛋白及其应用 | |
Ingraham et al. | The mouse Thy-1.2 glycoprotein gene: complete sequence and identification of an unusual promoter. | |
CN114507274B (zh) | 可逆结合生物素的链霉亲和素突变蛋白及其应用 | |
CN106822184A (zh) | 多靶点联合的car‑t细胞制剂与制备方法 | |
Di Rocco et al. | Interplay of the E box, the cyclic AMP response element, and HTF4/HEB in transcriptional regulation of the neurospecific, neurotrophin-inducible vgf gene |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
CI01 | Publication of corrected invention patent application |
Correction item: Priority Correct: 08103958.8 20080514 EP False: 08159754.4 20080704 EP Number: 01 Volume: 26 |
|
CI02 | Correction of invention patent application |
Correction item: Priority Correct: 08103958.8 20080514 EP False: 08159754.4 20080704 EP Number: 01 Page: The title page Volume: 26 |
|
ERR | Gazette correction |
Free format text: CORRECT: PRIORITY; FROM: 08159754.4;20080704;EP TO: 08103958.8;20080514;EP |
|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20100106 |